Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Acquired by Tocqueville Asset Management L.P.

Tocqueville Asset Management L.P. increased its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 42.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 22,400 shares of the biotechnology company’s stock after acquiring an additional 6,700 shares during the period. Tocqueville Asset Management L.P. owned approximately 0.08% of Arcturus Therapeutics worth $380,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Arcturus Therapeutics by 10.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company’s stock valued at $202,000 after buying an additional 846 shares in the last quarter. Nordea Investment Management AB raised its stake in shares of Arcturus Therapeutics by 3.7% during the fourth quarter. Nordea Investment Management AB now owns 65,778 shares of the biotechnology company’s stock valued at $1,097,000 after purchasing an additional 2,335 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Arcturus Therapeutics by 1.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 197,622 shares of the biotechnology company’s stock valued at $4,587,000 after purchasing an additional 3,224 shares during the period. SG Americas Securities LLC raised its stake in shares of Arcturus Therapeutics by 45.0% during the fourth quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company’s stock valued at $203,000 after purchasing an additional 3,705 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Arcturus Therapeutics by 1.1% during the third quarter. Geode Capital Management LLC now owns 551,798 shares of the biotechnology company’s stock valued at $12,810,000 after purchasing an additional 5,789 shares during the period. 94.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ARCT shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Friday, March 7th. HC Wainwright dropped their price objective on shares of Arcturus Therapeutics from $63.00 to $60.00 and set a “buy” rating on the stock in a research note on Friday, March 7th. Wells Fargo & Company dropped their price target on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, March 7th. Canaccord Genuity Group dropped their price target on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating for the company in a research note on Monday, March 10th. Finally, BTIG Research set a $48.00 price target on shares of Arcturus Therapeutics and gave the stock a “buy” rating in a research note on Monday, March 10th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Arcturus Therapeutics currently has a consensus rating of “Buy” and an average target price of $59.20.

Arcturus Therapeutics Price Performance

ARCT stock opened at $13.40 on Thursday. Arcturus Therapeutics Holdings Inc. has a 1-year low of $12.75 and a 1-year high of $45.00. The firm has a fifty day moving average price of $16.29 and a two-hundred day moving average price of $18.16. The firm has a market cap of $363.41 million, a price-to-earnings ratio of -6.04 and a beta of 2.96.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.78). Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The firm had revenue of $22.77 million for the quarter, compared to analyst estimates of $44.64 million. As a group, analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current fiscal year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.